Naloxone-precipitated opioid abstinence is associated with enhancement of reflex responses to noxious stimulation (hyperalgesia).
The present experiments in lightly anesthetized rats were designed to determine (1) whether neurons in the rostra1 ventromedial medulla (RVM) contribute to this enhancement, and (2) whether this enhancement is due to removal of an inhibitory modulatory influence or to activation of a facilitatory influence.
In the first experiment, 10 cg of morphine was microinjected into the RVM; subsequent administration of naloxone (1 mg/kg, i.v.) shortened tail-flick latency. This is evidence that a synaptic action of opioids within the RVM can contribute to hyperalgesia. In the second experiment, systemic administration of morphine (2 mg/kg, i.v.) was followed by systemic administration of naloxone (1 mg/kg, i.v.), which produced a significant hyperalgesia that could be markedly attenuated by microinjection of 10 pg lidocaine into the RVM. That inactivation of RVM reduces the hyperalgesia indicates that the CNS is capable of generating a facilitating action on nociceptive transmission. Previous studies from this laboratory have indicated that a population of RVM neurons, on-cells, shows increased activity during opioid abstinence.
The present experiments support the hypothesis that RVM on-cells exert a facilitating influence on nociceptive transmission.
Opioids produce potent analgesia in humans, and in animals, they increase the threshold for reflex responses to noxious stimuli. These antinociceptive effects occur whether opioids are given systemically (Fields, 1985) , intrathecally (Yaksh, 198 l) , or supraspinally (Yeung and Rudy, 1980; Yaksh et al., 1988) . Conversely, when opioid administration is either abruptly terminated or followed by administration of an antagonist, an abstinence syndrome appears during which human subjects report spontaneous pain (Jaffe, 1985; Heishman et al., 1989) and in animals there is an enhancement of reflex responses to noxious stimuli (Kayan et al., 1971; Kosersky et al., 1974; Bickel et al., 1988) . The hyperalgesia observed during opioid abstinence could result from reduction of a tonic inhibitory modulation that was present prior to drug administration. An important alternative, however, is that it is the consequence of the activation of modulatory neurons that facilitate nociceptive transmission. An extensive body of evidence has implicated neurons in specific brainstem sites in nociceptive modulation (Basbaum and Fields, 1984; Fields et al., 1988; Willis, 1988) . Neurons in the rostra1 ventromedial medulla (RVM), which includes the nucleus raphe magnus, nucleus gigantocellularis pars alpha, and the adjacent reticular formation, are of particular interest, because they are part of a well-established pathway for nociceptive modulation. The RVM projects densely to spinal and trigeminal dorsal horn laminae containing neurons implicated in nociceptive transmission, and electrical stimulation of or glutamate microinjected into the RVM elicits antinociceptive effects (Basbaum and Fields, 1984) . There is also evidence that the RVM plays an important role in opioid modulation of nociception. Microinjection of opioids into the RVM produces naloxonereversible antinociception, and lesions of or naloxone injections into the RVM reduce the effectiveness of systemically administered morphine (Proudfit and Anderson, 1975; Akaike et al., 1978; Dickenson et al., 1979; Azami et al., 1982; Jensen and Yaksh, 1986) .
Most of the experimental observations on this brainstem-todorsal horn modulatory pathway have focused on its inhibitory actions on nociceptive transmission (e.g., Basbaum and Fields, 1984) . Recent experiments, however, have raised the possibility that this pathway also has a facilitating action on nociception. Light et al. (1986) have shown that electrical stimulation of RVM can cause an early depolarization in some dorsal horn nociceptive neurons. Although dorsal horn neurons excited by stimulation of brainstem modulatory regions may be inhibitory interneurons, Zhuo and Gebhart (1990) have recently reported that low-intensity electrical stimulation of RVM shortens the latency to tail flick (TF) evoked by noxious heat. In addition, enhancement of nocifensor responses can be produced in opioiddependent animals by naloxone microinjected into the periaqueductal gray (PAG; Wilcox et al., 1979) , a region that projects indirectly to the spinal cord dorsal horn by way of the RVM (Behbehani and Fields, 1979; Abols and Basbaum, 198 1; Beitz et al., 1983) . Because opioid microinjection into the PAG concomitantly affects RVM neuronal firing and reflex responses to noxious stimulation (Cheng et al., 1986) , it is possible that the hyperalgesic effect generated by neurons in the PAG during opioid abstinence is exerted via the RVM.
In the present studies, the possibility that RVM can generate or relay a facilitating effect on nociceptive transmission was investigated by microinjecting morphine into RVM and then inducing withdrawal by systemic administration of naloxone. produced antinociception, and in all rats the subsequent systemic administration of naloxone (1 mg/kg) resulted in hyperalgesia. Open circles represent sites where the bilateral microinjection of morphine did not produce antinociception, and in these rats the subsequent administration of naloxone did not affect TF latency.
Significant shortening of TF latency was observed, suggesting that the RVM can contribute to the hyperalgesia of opioid abstinence. However, because an enhancement of nociceptive transmission could result from direct facilitation or loss of inhibition, this experiment left open the question of whether neurons in the RVM are capable of generating an active facilitation. The second experiment was designed to address this question by microinjecting lidocaine into the RVM to diminish all neural activity and thus remove the output of the RVM. During naloxone-precipitated opioid withdrawal, lidocaine microinjected in RVM decreased nociceptive responsiveness (i.e., reduced the hyperalgesia), thus supporting the presence of a distinct nociceptive facilitatory output from the RVM.
Materials and Methods
Animals. Male Sprague-Dawley rats weighing 250-275 gm were initially anesthetized with sodium pentobarbital(60 mg/kg, i.p. placed in each external jugular vein. The animal was then placed in a stereotaxic frame, and a small craniotomy was drilled posterior to the lambdoidal suture. Two 25-gauge stainless-steel guide cannulas separated by 0.5 mm in the coronal plane were lowered towards the RVM. Body temperature was stabilized throughout the experiments by a circulating water blanket maintained at 37°C. The animal was then allowed to recover from the initial anesthetic until a tail-flick reflex could be elicited in response to noxious heat. A continuous infusion of methohexital (15-30 mg/kg/hr, i.v.) was then started. The animal was thus maintained in a lightly anesthetized state with no obvious signs of discomfort. Nociceptive testing was initiated 45 min after starting the methohexital infusion.
Intracerebral microinjections were made into the RVM with two 3 lgauge injection cannulas attached to polyethylene tubing (PE 20) connected to 1.0-g Hamilton syringes. The injection cannulas were inserted into the RVM before the initiation of behavioral testing and were left in place for the duration of the experiment. The progress of the injection was monitored via the movement of an air bubble through the tubing.
Drugs. In the first series of experiments, either morphine or saline (0.9%) was microiniected into the RVM. A volume of 0.5 d was simultaneously microinjected on each side of the midline (5 ig of morphine was injected on each side). Twenty-five minutes later, naloxone ( 1 mg/kg) was administered intravenously. Microinjections of morphine were also made either dorsal or rostra1 to RVM as placement controls.
In the second series of experiments, morphine (2 mg/kg) or saline was injected intravenously. Naloxone was administered 25 min later (1 mg/kg, i.v., in 0.3 ml). The doses of morphine and naloxone that were selected were those that were previously established in this laboratory to induce a maximal hyperalgesic response in lightly anesthetized rats (Rim et al.. 1990 ). All iniections were followed bv a O.&ml saline flush , , of the catheter. Four minutes following the administration of naloxone, either 0.5 ~1 saline (0.9%) or 10 ~a lidocaine in the same volume of saline was microinjected into each side of the RVM over a 2-min period. The dose of lidocaine selected was known to decrease the threshold to elicit a nocifensive reflex when microinjected into RVM in lightly anesthetized, opioid-naive rats (M Morgan, unpublished observations). Control microinjections were also made either dorsal or rostra1 to RVM.
Nociceptive testing. The tail-flick reflex evoked by noxious heat was used as the index of nociceptive responsiveness. The stimulus was a linear temperature ramp that rose from a holding temperature of 35°C to 52°C in 10 sec. A small thermistor probe was placed in contact with the heated site on the blackened ventral surface of the tail and provided a signal for the feedback-controlled projection lamp. The heat was automatically terminated at 10 set or upon occurrence of a flick. Tail-flick (TF) trials were initiated everv 3 min at three tail sites 3, 5. and 7 cm from the distal tip of the tail; used in rotation. The baseline tail-flick latency was taken as the average latency of the last three of five TF trials. Following the first intravenous drug injection, there was a lomin hiatus in testing.
For the purpose of this paper, the term "hyperalgesia" will be used to denote a shortening of TF latency below the premorphine baseline level. The use of this term does not imply a specific mechanism, nor is it meant to imply that the rats actually feel greater pain.
An external temperature probe (YSI 427) was taped 4 cm from the base of the tail on the ventral surface to allow constant monitoring of tail-skin temperature (TS temp) proximal to the site of the heat stimulus used to evoke the TF. This was necessary because Katovich et al. (1987) have demonstrated that there is a surge in rat TS temp, as well as a decrease in core body temperature, during systemic naloxone-precipitated opioid withdrawal. Because a change&t this parameter could affect the TF latencv (Ness and Gebhart. 1986: Eide and Rosland. 1989) . the TS temp was-monitored by both the thermistor probe controlling the heat stimulus and a more proximal skin temperature probe.
Histology. At the end of the experiment, the animal was killed with an overdose of methohexital and intracardially perfused first with saline, then with 10% formalin. The sites of all injection cannulas were verified histologically.
Statistical analysis. Tail-flick latency is presented as mean and standard error of the mean (SEM). Differences between groups were determined using a repeated-measures analysis of variance (ANOVA) followed by Tukey's post hoc analysis. TS temp is reported as mean and SEM and absolute range of temperature where appropriate. TS temp data were analyzed with a repeated-measures ANOVA and Tukey's post hoc analysis.
Results

Experiment 1
The first series of experiments addressed the contribution of the RVM to the hyperalgesia that is part of the naloxone-precipitated opioid-abstinence syndrome. Either saline (n = 6) or 10 pg morphine (n = 6) was microinjected into the RVM (see Fig.  1 for locations). The effect of the subsequent intravenous administration of naloxone on TF latency and proximal tail temperature was studied (Fig. 2) . ANOVA revealed significant differences between groups (F = 50.4; p < 0.0 1) and between trials (F = 13.7; p < 0.01). The mean baseline TF latency for the RVM saline group was 4.8 + 0.18 set, and for the RVM morphine group, it was 4.7 + 0.17 set, with no significant difference between the two groups (Tukey, p > 0.05). Neither microinjection of saline into the RVM nor administration of intravenous naloxone after RVM saline produced a significant change in the TF latency compared to baseline (Tukey, p > 0.05).
The six rats that received morphine into the RVM exhibited an increase in TF latency to the 1 0-set cutoff time following the microinjection. In these rats the subsequent administration of naloxone resulted in a reduction of the TF latency to below baseline (i.e., hyperalgesia). At 15 min postnaloxone, the mean latency was 2.3 f 0.17 sec. This was significantly lower than the premorphine baseline latency (Tukey, p < 0.01) and was significantly lower at the same postnaloxone time point than the 4.6 +_ 0.2-set mean TF latency of the rats that had received RVM microinjection of saline (Tukey, p < 0.01; Fig. 2) .
In 12 rats, morphine was microinjected outside the area of the RVM (Fig. 1) . The mean baseline TF latency was 4.8 + 0.17 set, which was not different from the baselines of the other two groups of rats in this series of experiments. In these 12 rats, morphine produced no change in TF latency, nor did the sub- Thus, the occurrence of the hyperalgesia appears to depend on injection of morphine into sites that are capable of blocking the TF response.
Tail-skin temperature Naloxone given after morphine microinjection into the RVM did not cause a significant change in the TS temp across trials (F = 1.6; p > 0.05) or compared to rats receiving naloxone after saline microinjected into the RVM (F = 1.8; p > 0.05).
Experiment 2
The second series of experiments addressed the contribution of the RVM to the hyperalgesia associated with naloxone-precipitated withdrawal from systemically administered morphine. ANOVA on TF latencies revealed significant differences between groups (F = 62.4; p < 0.0 1) and between trials (F = 45.4; p < 0.01). The baseline TF latency for the four groups in the second series ranged from 4.5 to 4.8 set, with no significant differences between the four groups (Tukey, p > 0.05). Differences in TF latency were first seen following naloxone administration. Rats receiving naloxone after morphine had significantly shorter TF latencies than saline-pretreated rats receiving naloxone (Tukey, p < 0.05). In those rats receiving intravenous saline as their first drug (Table 1 , groups I, II), the TF latency did not differ from baseline. Furthermore, in these rats, the TF latency was not changed by intravenous naloxone.
Lidocaine in R VM Lidocaine (10 pg) microinjected bilaterally into the RVM of rats that had not received morphine resulted in a decrease in TF latency to 67% of baseline (Table 1 , group II). This hyperalgesia was maximal at 7-l 3 min following the microinjection (Fig. 3) . In contrast, no decrease in TF latency was observed in similarly treated rats that received saline microinjected into the RVM (Table 1 , group I). The difference between these two groups was significant (Tukey, p < 0.01). There were significant changes in TS temp in the four groups of this experiment (F = 22.3; p < 0.01). However, groups of rats receiving intravenous saline (groups I and II) showed only minor increases in TS temp (0.5 f 0.2%) and did not differ significantly from each other at any time point (Tukey, p > 0.05).
Systemic naloxone following systemic morphine Intravenous administration of morphine resulted in an increase in the TF latency to the 1 0-set cutoff time in all rats (Table 1 , groups III, IV). The systemic administration of naloxone following intravenous morphine resulted in a significant decrease in TF latency from baseline (i.e., hyperalgesia) in these two groups at 3 min postnaloxone. In group III, saline was microinjetted into the RVM. In this group, the peak of the hyperalgesia was 10-19 min following administration of naloxone (Fig. 4 , open circles). Figure 5 . Paired microinjected sites for lidocaine are shown. Rats given systemic morphine (2 mg/kg) followed by systemic naloxone (1 mg/kg) displayed a significant decrease in TF latency (hyperalgesia). Solid squares represent sites where the bilateral microinjection of lidocaine significantly attenuated the hyperalgesia of acute opioid abstinence. Open squares represent sites of lidocaine microinjections that were ineffective in attenuating the hyperalgesia.
During naloxone-precipitated morphine withdrawal, the TS temp increased an average of 3.X (from an initial temperature range of 22-26°C to a maximum temperature ranging from 26°C to 30°C); this is helow the 35°C holding temperature of the Fifteen minutes postnaloxone 4.5 * 0.11 3.1 + 0.14 2.1 + 0.12 3.7 f 0.11 thermal stimulator used to elicit the TF. Only animals that received intravenous morphine followed by intravenous naloxone exhibited significant changes in TS temp compared to their baseline values (Tukey, p < 0.05). Rats that received intravenous naloxone following intravenous saline showed no changes in TS temp compared to baseline (Tukey, NS).
Eflect of lidocaine on the hyperalgesia of acute opioid abstinence Lidocaine microinjected bilaterally into the RVM caused a significant attenuation of the hyperalgesia of animals that had received intravenous morphine followed by intravenous naloxone (see Table 1 , group IV). At 15 min following administration of naloxone, rats that received lidocaine in the RVM had a mean TF latency of 3.8 + 0.11 set; at this time, rats that had received a microinjection of saline had a significantly shorter TF latency of 2.1 f 0.12 set (Tukey, p < 0.05; Fig. 4) . The hyperalgesia reducing effect of the lidocaine was maximal 7-13 min following the RVM microinjection. When the lidocaine was microinjected outside the boundaries of the RVM (Fig. S) , either 2 mm dorsal in the medial longitudinal fasciculus (n = 6) or 2 mm rostra1 (i.e., at the rostra1 pole of the superior olive; n = 6) in animals that had received intravenous morphine followed by intravenous naloxone, the hyperalgesia was not attenuated. The TF latency did not differ significantly from that observed in similarly treated rats that received saline microinjected into the RVM (F = 2.7; p > 0.05).
Despite the attenuation ofthe hyperalgesia by RVM lidocaine, the surge in TS temp produced by intravenous naloxone in rats receiving intravenous morphine was not reduced by the microinjection of lidocaine into RVM (Tukey, p > 0.05).
Discussion
The present experiments have demonstrated that lidocaine microinjected into the RVM reduces the enhanced response to noxious stimuli that occurs during opioid abstinence. This observation directly implicates the RVM in a supraspinal modulatory network that is capable of generating an active facilitation of responses to noxious stimuli.
Skin temperature during opioid abstinence The administration of naloxone to animals that had received systemic morphine caused a surge in TS temp during the period of naloxone-precipitated withdrawal.
In the present experiments, the changes in TS temp were less than that previously reported (Katovich et al., 1987) , and it appears unlikely that these changes significantly affected TF latency in the current experiments. First, despite the small increases in proximal TS temp, the 35°C holding temp of the TF apparatus is above the peak TS temp observed during naloxone-induced abstinence, thus ensuring that all imposed thermal stimuli began from the same baseline. Second, rats with different TS temp, as measured at a site remote from the tail area heated, exhibited similar TF latencies. For example, animals that received RVM microinjection of morphine and animals that received systemic morphine exhibited similar degrees of hyperalgesia following administration of naloxone; however, only the latter group exhibited any changes in TS temp. Therefore, the changes in TS temp that occur during the naloxone-precipitated abstinence syndrome do not contribute significantly to the observed shortening of TF latency. This not only confirms the independence of the proximal TS temp and the hyperalgesia, but also indicates that the RVM does not contribute to the temperature increase observed during naloxone-precipitated opioid abstinence.
Evidence for a nociceptive facilitating output from R VA4 The present studies confirm previous observations that opioid abstinence is associated with enhanced responsiveness to noxious stimuli (Wilcox et al., 1979; Kim et al., 1990) . This enhancement could result from active facilitation or removal of inhibition of nociceptive transmission or both. If the enhancement resulted from an RVM facilitatory effect on nociceptive transmission, then it should be attenuated by the removal ,of the RVM output during withdrawal. If, on the other hand, the enhancement were due solely to removal of an inhibitory influence, then inactivation of the RVM during abstinence should either have no additional effect or further increase the hyperalgesia. Because it is markedly attenuated by lidocaine in the RVM, the hyperalgesia of opioid abstinence is due to activation of a facilitating output. A corollary of this is that the RVM is capable of generating an output that increases responsiveness to noxious stimulation. Although lidocaine affects both neurons and fibers of passage, the fact that hyperalgesia can be produced by naloxone after morphine microinjected into RVM supports the idea that RVM neurons facilitate nociceptive transmission. The use of drugs such as GABA agonists to inactivate selectively RVM neurons might be helpful to define further the contribution of RVM neurons versus fibers of passage.
It is possible that the nocifensor reflex enhancement observed during opioid abstinence actually reflects facilitation of motoneurons rather than a specific effect upon dorsal horn intemeurons involved in nociceptive transmission. Although the rostra1 RVM projects specifically to dorsal horn and autonomic nuclei, and the nociceptive modulatory pathway running from the PAG to RVM to spinal cord is not known to affect motoneurons directly, the observed increased responses could derive from drug effects upon nearby nuclei (such as nucleus raphe pallidus) that project directly to the ventral horn. Specific studies will be required to resolve this issue.
Opposing eflects of lidocaine in opioid-naive and opioiddependent rats As discussed above, lidocaine injected into the RVM during opioid abstinence reduces responsiveness to noxious stimulation. In contrast, the present experiments have confirmed the previous observations that, in opioid-naive rats, inactivation of RVM neurons by lesions or local anesthetic enhances responsiveness to noxious stimulation (Proudfit, 1975 (Proudfit, , 1980 Sandkuhler and Gebhart, 1984) . The opposing effects of inactivation of RVM neurons are most simply explained by assuming that the output of RVM differs under these two conditions. In other words, in opioid-abstinent rats, the net output of RVM is facilitatory; thus, inactivation of RVM reduces behavioral responses to noxious stimulation. In opioid-naive rats, the net output of RVM is inhibitory, and thus inactivation of RVM results in enhancement of responses to noxious stimulation. These assumptions receive support from physiological studies of RVM neurons under conditions similar to those of the present experiments (Bederson et al., 1990 whose activity is correlated with nocifensor reflexes (Fields et al., 1988) . One class is consistently inhibited by stimuli in the noxious range applied over wide areas of the body surface. The firing of this cell class abruptly slows just prior to the occurrence of a withdrawal reflex. This cell class, termed the "off-cell," fires continuously following administration of morphine in doses that block nocifensive reflexes (Fields et al., 1983 (Fields et al., , 1988 . The second, class of cell exhibits a firing pattern reciprocal to that of the off-?, cell and is called the "on-cell" (Barbaro et al., 1986 Oliveras et al., 1989) . The on-cell bursts prior to reflexes elicited by noxious stimuli and is inhibited by morphine. There is independent evidence correlating the spontaneous firing of a given RVM cell class with changes in the TF latency. In the lightly anesthetized rat, all cells of each physiological class show tightly correlated periods of activity . Heinricher et al. (1989) have demonstrated that, if noxious heat is applied during a period of on-cell activity, the TF latency is significantly shorter than if the same stimulus is given during a period of off-cell activity.
Electrical stimulation or the microinjection of glutamate in the RVM usually results in antinociception (Zorman et al., 198 1; Satoh et al., 1983; Jensen and Yaksh, 1984) . These manipulations should have only direct excitatory effects on RVM neurons, which implies that there is a class of RVM neurons whose activity leads to inhibition of nociceptive transmission at the spinal cord. Several lines of evidence support the hypothesis that the off-cell is the RVM inhibitory output cell (for review, see Fields et al., 1988) .
During naloxone-precipitated opioid withdrawal, off-cells are silent or relatively inactive, while on-cell firing is markedly increased (Bederson et al., 1990) . This increase in on-cell activity during opioid withdrawal was shown to be correlated in both time and magnitude with an increase in reflex responses to noxious input (hyperalgesia). Because the hyperalgesia of the opioid-abstinence syndrome is blocked by inactivation of the RVM, it is likely that some neural element within RVM actively facilitates nociceptive transmission. Because off-cells are relatively silent and on-cells show increased activity during opioid abstinence, the present results are consistent with the conclusion that the reduction of hyperalgesia by RVM lidocaine is due to its inactivation of the on-cell. Although inactivation of fibers of passage or some other, unidentified nerve cell class within RVM could account for the lidocaine effect, the present data support the hypothesis that on-cells provide a functional output from the RVM that is facilitatory to nocifensor reflexes.
Nociceptive modulating pathways may contribute to the hyperalgesia of opioid abstinence It is generally accepted that neurons in the brainstem contribute to the antinociceptive actions of systemically administered opioids (Dickenson et al., 1979; Azami et al., 1982; Fields, 1985; Jensen and Yaksh, 1986 ). The present observation that, following morphine microinjection into the RVM, systemic naloxone facilitates nocifensor reflexes suggests that neurons in the RVM also contribute to the hyperalgesia of the opioid-abstinence syndrome. Although there is obviously much more to the opioidabstinence syndrome than hyperalgesia (Ritzman, 198 1; Jaffe, 1985) , the reduction by RVM lidocaine of the hyperalgesia observed when systemic naloxone is given following systemic morphine suggests that changes in the nociceptive modulatory pathway are an important part of the mechanism of acute physical dependence. Support for this concept comes from an observation by Bozarth and Wise (1984) , who found that systemic naloxone can induce an abstinence syndrome (including escape behavior) in rats after infusion of morphine into the PAG area. In addition, Wilcox et al. (1979) found that naloxone microinjetted into the PAG can induce hyperalgesia in rats made physically dependent by systemic morphine.
An interesting implication of the present findings is that facilitation of nociceptive transmission may contribute to the aversiveness of opioid withdrawal. In other words, the hyperresponsiveness during opioid abstinence that is observed in animals may be a meaningful correlate of increased perceived pain intensity and/or an aversive signal. In unanesthetized rats, naloxone injected into the PAG region of opioid-tolerant rats results in escape behavior (Wei and Loh, 1976; Wilcox et al., 1979) , and in human subjects, increased reports of pain are a common feature ofthe opioid-abstinence syndrome (Jaffe, 1985; Heishman et al., 1989) .
